Bech-Bruun Advises Medtronic on Carve-Out and Nasdaq Listing of MiniMed Group, Inc. (Valued at

Bech-Bruun Advises Medtronic on Carve-Out and Nasdaq Listing of MiniMed Group, Inc. (Valued at > USD 5.3B)

"Bech-Bruun advised Medtronic plc on the Danish aspects of the carve-out and spin-off of its diabetes business, MiniMed Group, Inc. MiniMed was listed on Nasdaq on March 6, 2026, with a valuation above USD 5.3 billion. MiniMed is a leader in insulin delivery; Medtronic is a global healthcare technology company with over 95,000 employees. Bech-Bruun’s core team was Mikkel Anker Heegaard and Oliver Bolding Rasmussen; Baker McKenzie acted as global counsel."

Bech‑Bruun and Baker McKenzie participated in the transaction: Bech‑Bruun assisted Medtronic plc on the Danish aspects of the carve‑out and spin‑off of its diabetes business, MiniMed Group, Inc., and Baker McKenzie acted as global counsel in the transaction. The transaction involved the carve‑out and spin‑off of Medtronic’s diabetes business, MiniMed Group, Inc., which was listed on Nasdaq on March 6, 2026, with a value exceeding USD 5.3 billion. Medtronic is a global healthcare technology company with over 95,000 employees in more than 150 countries, and MiniMed is a leader in insulin delivery. Lawyers of the participating firms named in the press release: - Bech‑Bruun: Mikkel Anker Heegaard; Oliver Bolding Rasmussen. (The press release does not specify their seniority or practice area.) - Baker McKenzie: no individual lawyers were named in the press release.

Menu

Bech-Bruun Advises Medtronic on Carve-Out and Nasdaq Listing of MiniMed Group, Inc. (Valued at > USD 5.3B)

Read the full story

Menu

Bech-Bruun Advises Medtronic on Carve-Out and Nasdaq Listing of MiniMed Group, Inc. (Valued at > USD 5.3B)

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads